Yujie Ding1, Yu Zhong1, Andrea Baldeshwiler2, Erin L Abner1,3, Björn Bauer4, Anika M S Hartz5,6,7. 1. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA. 2. Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota, 55812, USA. 3. Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, 40536, USA. 4. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, 40536, USA. 5. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA. anika.hartz@uky.edu. 6. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA. anika.hartz@uky.edu. 7. University of Kentucky Sanders-Brown Center on Aging, 800 S Limestone, Lexington, KY, 40536, USA. anika.hartz@uky.edu.
Abstract
BACKGROUND: Failure to clear Aβ from the brain is partly responsible for Aβ brain accumulation in Alzheimer's disease (AD). A critical protein for clearing Aβ across the blood-brain barrier is the efflux transporter P-glycoprotein (P-gp). In AD, P-gp levels are reduced, which contributes to impaired Aβ brain clearance. However, the mechanism responsible for decreased P-gp levels is poorly understood and there are no strategies available to protect P-gp. We previously demonstrated in isolated brain capillaries ex vivo that human Aβ40 (hAβ40) triggers P-gp degradation by activating the ubiquitin-proteasome pathway. In this pathway, hAβ40 initiates P-gp ubiquitination, leading to internalization and proteasomal degradation of P-gp, which then results in decreased P-gp protein expression and transport activity levels. Here, we extend this line of research and present results from an in vivo study using a transgenic mouse model of AD (human amyloid precursor protein (hAPP)-overexpressing mice; Tg2576). METHODS: In our study, hAPP mice were treated with vehicle, nocodazole (NCZ, microtubule inhibitor to block P-gp internalization), or a combination of NCZ and the P-gp inhibitor cyclosporin A (CSA). We determined P-gp protein expression and transport activity levels in isolated mouse brain capillaries and Aβ levels in plasma and brain tissue. RESULTS: Treating hAPP mice with 5 mg/kg NCZ for 14 days increased P-gp levels to levels found in WT mice. Consistent with this, P-gp-mediated hAβ42 transport in brain capillaries was increased in NCZ-treated hAPP mice compared to untreated hAPP mice. Importantly, NCZ treatment significantly lowered hAβ40 and hAβ42 brain levels in hAPP mice, whereas hAβ40 and hAβ42 levels in plasma remained unchanged. CONCLUSIONS: These findings provide in vivo evidence that microtubule inhibition maintains P-gp protein expression and transport activity levels, which in turn helps to lower hAβ brain levels in hAPP mice. Thus, protecting P-gp at the blood-brain barrier may provide a novel therapeutic strategy for AD and other Aβ-based pathologies.
BACKGROUND: Failure to clear Aβ from the brain is partly responsible for Aβ brain accumulation in Alzheimer's disease (AD). A critical protein for clearing Aβ across the blood-brain barrier is the efflux transporter P-glycoprotein (P-gp). In AD, P-gp levels are reduced, which contributes to impaired Aβ brain clearance. However, the mechanism responsible for decreased P-gp levels is poorly understood and there are no strategies available to protect P-gp. We previously demonstrated in isolated brain capillaries ex vivo that human Aβ40 (hAβ40) triggers P-gp degradation by activating the ubiquitin-proteasome pathway. In this pathway, hAβ40 initiates P-gp ubiquitination, leading to internalization and proteasomal degradation of P-gp, which then results in decreased P-gp protein expression and transport activity levels. Here, we extend this line of research and present results from an in vivo study using a transgenic mouse model of AD (human amyloid precursor protein (hAPP)-overexpressing mice; Tg2576). METHODS: In our study, hAPP mice were treated with vehicle, nocodazole (NCZ, microtubule inhibitor to block P-gp internalization), or a combination of NCZ and the P-gp inhibitor cyclosporin A (CSA). We determined P-gp protein expression and transport activity levels in isolated mouse brain capillaries and Aβ levels in plasma and brain tissue. RESULTS: Treating hAPP mice with 5 mg/kg NCZ for 14 days increased P-gp levels to levels found in WT mice. Consistent with this, P-gp-mediated hAβ42 transport in brain capillaries was increased in NCZ-treated hAPP mice compared to untreated hAPP mice. Importantly, NCZ treatment significantly lowered hAβ40 and hAβ42 brain levels in hAPP mice, whereas hAβ40 and hAβ42 levels in plasma remained unchanged. CONCLUSIONS: These findings provide in vivo evidence that microtubule inhibition maintains P-gp protein expression and transport activity levels, which in turn helps to lower hAβ brain levels in hAPP mice. Thus, protecting P-gp at the blood-brain barrier may provide a novel therapeutic strategy for AD and other Aβ-based pathologies.
Authors: Anika M S Hartz; Anton Pekcec; Emma L B Soldner; Yu Zhong; Juli Schlichtiger; Bjoern Bauer Journal: Mol Pharm Date: 2017-03-02 Impact factor: 4.939
Authors: Pavitra Kannan; Martin Schain; Warren W Kretzschmar; Lora Weidner; Nicholas Mitsios; Balázs Gulyás; Hans Blom; Michael M Gottesman; Robert B Innis; Matthew D Hall; Jan Mulder Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: Catherine Chiu; Miles C Miller; Renée Monahan; Doreen P Osgood; Edward G Stopa; Gerald D Silverberg Journal: Neurobiol Aging Date: 2015-06-06 Impact factor: 4.673
Authors: Daniëlle M E van Assema; Mark Lubberink; Ronald Boellaard; Robert C Schuit; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel Journal: Mol Imaging Biol Date: 2012-12 Impact factor: 3.488